unnamed.png

 Presenting Companies Include:

unnamed.png

 

 

   
  
   
  
    
  
   Normal 
   0 
   
   
   
   
   false 
   false 
   false 
   
   EN-US 
   JA 
   X-NONE 
   
    
    
    
    
    
    
    
    
    
   
   
    
    
    
    
    
    
    
    
    
    
    
    
    
  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
   
 
 /* Style Definitions */
table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;}
 
    Allegro Ophthalmics, LLC is establishing integrin peptide therapy as the next-generation pharmaceutical category for the treatment of diabetic macular edema (DME).  Allegro’s lead investigational drug, risuteganib (Luminate), has successfully met the endpoints for three Phase 2 studies and is now cleared for US phase 3 studies in DME. In the phase 2 studies, Luminate has demonstrated the ability to reduce the current burden of intravitreal injections with 12 week durability and to treat anti-VEGF non-responsive DME patients by simultaneously targeting all four oxidative stress pathways.  By bringing to market new and improved treatment options for leading causes of blindness, Allegro is committed to offering patients an improved quality of life sustained by self-sufficient, functional vision.   Vicken Karageozian, MD, President and CMO

Allegro Ophthalmics, LLC is establishing integrin peptide therapy as the next-generation pharmaceutical category for the treatment of diabetic macular edema (DME).  Allegro’s lead investigational drug, risuteganib (Luminate), has successfully met the endpoints for three Phase 2 studies and is now cleared for US phase 3 studies in DME. In the phase 2 studies, Luminate has demonstrated the ability to reduce the current burden of intravitreal injections with 12 week durability and to treat anti-VEGF non-responsive DME patients by simultaneously targeting all four oxidative stress pathways.  By bringing to market new and improved treatment options for leading causes of blindness, Allegro is committed to offering patients an improved quality of life sustained by self-sufficient, functional vision. 

Vicken Karageozian, MD, President and CMO

    Eyedaptic’s unique Software for retina-related vision loss, embedded in Augmented Reality glasses, simulate natural vision to restore a complete field of vision to help sufferers lead fuller lives. For sufferers in the advanced stages of Age-Related Macular Degeneration (AMD), the world has disappeared before their eyes. These AMD sufferers have lost their central vision and the ability to see and to do many of the things they love, like read, recognize the faces of family and friends, work and watch T.V. Equipped with patent pending EYEdaptiveTM simulated natural vision software embedded in wearable AR glasses, the Company’s solution optimizes the sufferer’s functional peripheral vision to help restore the entire scene for the wearer. Unlike other visual aids that use only magnification, thereby reducing the user’s field of vision, our solution is customized to the user’s particular vision limitation and maximizes their field of view. The camera captures the surroundings, manipulates the pixels and re-displays the image where the user can see it. The adapted view for the wearer essentially takes advantage of the part of the retina that still functions well so the user sees the entire scene.   Jay Cormier, BSEE, MBA CEO, President and Founder 

 

Eyedaptic’s unique Software for retina-related vision loss, embedded in Augmented Reality glasses, simulate natural vision to restore a complete field of vision to help sufferers lead fuller lives. For sufferers in the advanced stages of Age-Related Macular Degeneration (AMD), the world has disappeared before their eyes. These AMD sufferers have lost their central vision and the ability to see and to do many of the things they love, like read, recognize the faces of family and friends, work and watch T.V. Equipped with patent pending EYEdaptiveTM simulated natural vision software embedded in wearable AR glasses, the Company’s solution optimizes the sufferer’s functional peripheral vision to help restore the entire scene for the wearer. Unlike other visual aids that use only magnification, thereby reducing the user’s field of vision, our solution is customized to the user’s particular vision limitation and maximizes their field of view. The camera captures the surroundings, manipulates the pixels and re-displays the image where the user can see it. The adapted view for the wearer essentially takes advantage of the part of the retina that still functions well so the user sees the entire scene. 

Jay Cormier, BSEE, MBA CEO, President and Founder 

 LensGen, Inc. is an Irvine, California-based clinical stage ophthalmic medical device company. In May of 2017 the company closed $23.8 million in Series A financing. The Financing was led by the corporate venture investment arm of Hoya Corporation and included participation from Relativity Healthcare Partners. The financing includes an option to expand the financing commitment by an additional $4.4 million. As the demand for premium IOLs is anticipated to grow significantly over the next several years, LensGen is well positioned to participate in the presbyopia and toric correcting IOL categories as well as the emerging adjustable IOL category because of its unique modular IOL design platform. The company’s flagship product Juvene is the world’s first modular curvature changing fluid IOL. On the strength of positive pilot study results, LensGen is planning to initiate an FDA pivotal trial in 2019 that will also include a toric version of the Juvene lens. The company’s most recent pilot outcomes demonstrated superior distance, intermediate and near vision compared to leading presbyopia correction IOLs.  Ramgopal Rao, CEO

LensGen, Inc. is an Irvine, California-based clinical stage ophthalmic medical device company. In May of 2017 the company closed $23.8 million in Series A financing. The Financing was led by the corporate venture investment arm of Hoya Corporation and included participation from Relativity Healthcare Partners. The financing includes an option to expand the financing commitment by an additional $4.4 million. As the demand for premium IOLs is anticipated to grow significantly over the next several years, LensGen is well positioned to participate in the presbyopia and toric correcting IOL categories as well as the emerging adjustable IOL category because of its unique modular IOL design platform. The company’s flagship product Juvene is the world’s first modular curvature changing fluid IOL. On the strength of positive pilot study results, LensGen is planning to initiate an FDA pivotal trial in 2019 that will also include a toric version of the Juvene lens. The company’s most recent pilot outcomes demonstrated superior distance, intermediate and near vision compared to leading presbyopia correction IOLs.

Ramgopal Rao, CEO

   
  
   
  
    
  
   Normal 
   0 
   
   
   
   
   false 
   false 
   false 
   
   DE 
   JA 
   X-NONE 
   
    
    
    
    
    
    
    
    
    
   
   
    
    
    
    
    
    
    
    
    
    
    
    
    
  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
   
 
 /* Style Definitions */
table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin-top:0in;
	mso-para-margin-right:0in;
	mso-para-margin-bottom:8.0pt;
	mso-para-margin-left:0in;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-ansi-language:DE;}
 
    Novaliq is a specialty pharmaceutical company focused on developing innovative ophthalmic products.  Founded in 2007 and based in Heidelberg, Germany, Novaliq develops first- and best-in-class ocular therapeutics based on EyeSol®, the company’s first and only water-free drug delivery technology. EyeSol® is the first and only technology overcoming the limitations of water-based eye drops, creating novel drugs with better bioavailability, efficacy, stability and tolerability. Novaliq has a very strong Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD) product pipeline, with assets that deploy multiple mechanisms of action. In the USA, more than 16 million patients are diagnosed with DED; however, with only two medical therapies available, this population is highly underserved, with fewer than 2 million receiving treatment. As a result, many patients use artificial tears, but these drops do not address the underlying disease causes. This significant gap between diagnosed and correctly treated patients is a clear indication that new and effective DED therapies are urgently needed.  With Novaliq’s late-staged pipeline in DED, we see our role in redefining how DED is understood and treated.   Bernhard Guenther, President      

Novaliq is a specialty pharmaceutical company focused on developing innovative ophthalmic products.  Founded in 2007 and based in Heidelberg, Germany, Novaliq develops first- and best-in-class ocular therapeutics based on EyeSol®, the company’s first and only water-free drug delivery technology. EyeSol® is the first and only technology overcoming the limitations of water-based eye drops, creating novel drugs with better bioavailability, efficacy, stability and tolerability. Novaliq has a very strong Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD) product pipeline, with assets that deploy multiple mechanisms of action. In the USA, more than 16 million patients are diagnosed with DED; however, with only two medical therapies available, this population is highly underserved, with fewer than 2 million receiving treatment. As a result, many patients use artificial tears, but these drops do not address the underlying disease causes. This significant gap between diagnosed and correctly treated patients is a clear indication that new and effective DED therapies are urgently needed.  With Novaliq’s late-staged pipeline in DED, we see our role in redefining how DED is understood and treated. 

Bernhard Guenther, President

 

 

SBA-PoweredBy[1].png

Funded in part through a Cooperative Agreement with the U.S. Small Business Administration. Funding is not an endorsement of any product, opinion, or service. All programs are extended to the public on a nondiscriminatory basis. Reasonable accommodations for persons with disabilities will be made if requested at least two weeks in advance. Please contact Katrina Smith at (657) 278-3195 or via  kmpayne@fullerton.edu